CDA基因多态性与晚期非小细胞肺癌患者含吉西他滨化疗疗效的研究

发布时间：2019-07-17 08:21

【摘要】：为了探讨胞苷脱氨酶(CDA)基因多态性与晚期非小细胞肺癌(NSCLC)患者含吉西他滨化疗疗效的关系。在试验中120例患者均接受含吉西他滨化疗,采用直接测学法检测化疗前CDA A79C和G208A的基因多态性,比较不同基因型与疗效的关系。结果表明CDA G208A位点中,基因型及等位基因与化疗有效率的差异无统计学意义,携带突变等位基因的基因型相对于野生型纯合子化疗无效的风险未升高(p=0.768);CDA A79C AA、AC、CC基因型的有效率依次为41.3%、20.0%和6.7%,A、C等位基因的有效率分别为37.8%和13.3%,差异均有统计学意义(p0.05);以野生型AA型为参照,突变基因型AC和CC化疗无效的风险均升高,且C等位基因相对于A等位基因化疗无效的风险也升高,差异均有统计学意义(p0.05)。CDA A79C多态性与化疗疗效有关,且携带突变等位基因患者化疗无效的风险较高,可以为临床个体化用药提供参考。
[Abstract]:To investigate the relationship between cytidine deaminase (CDA) gene polymorphism and the efficacy of gemcitabine chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). All 120 patients received gemcitabine chemotherapy. The gene polymorphism of CDA A79C and G208A before chemotherapy was detected by direct assay, and the relationship between different genotypes and curative effect was compared. The results showed that there was no significant difference in the efficacy of chemotherapy between CDA G208A and genotype G208A, but the risk of ineffective chemotherapy with mutant alleles was not higher than that of wild type homozygote (p 鈮，

本文编号：2515366